News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
News Conference News ACC 2023 MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis Michael O'Riordan March 10, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2021 Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM L.A. McKeown May 16, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2013 Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months Jason Kahn March 11, 2013